Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

A new therapy offers hopeful perspectives for patients suffering from spondyloarthropathy

07.03.2002


Spondyloarthropathies are rheumatic infectious diseases affecting the spinal column and peripheral joints and tendons. These diseases either occur as such (Bechterew`s disease or ankylosing spondylitis), or are combined with skin psoriasis, inflammatory intestinal diseases (Crohn`s disease and ulcerating colitis), and eye infection (uveitis).

These diseases effect about 1% of total world population and often develop into seriously debilitating conditions with complete stiffening of the spinal column and destruction of the peripheral joints (hips, knees, wrists and/or fingers). Thus far, treatment of these diseases has been limited to the administration of non-steroid anti-inflammatory drugs, which may have a benevolent effect on the subjective complaints of pain, but does not effect the evolution of the disease.

Tumor Necrosis Factor is a small molecule (a cytokine) which is released by the disposal cells (macrophages) of the immune systems at sites where the inflammation occurs and which, in case of spondyloarthropathy, induces changes in the bone, joints and tendons.


Two years ago the Department of Rheumatology of the University of Ghent, Belgium, initiated an open study involving the treatment of 21 patients suffering from various forms of these diseases with intravenous injections of a monoclonal antibody targeting the Tumor Nacrosis Factor (Infliximab). The results were impressive not only with regard to the complaints, but also with regard to the symptoms of infection of the spinal column and the peripheral sites, and the infection factors measured in the blood. These results were confirmed in a double blind study involving 40 other patients, the data that were published in the March 6, 2002 issue of Arthritis and Rheumatology, the leading scientific journal in the area of rheumatology.

The conclusion of the study can be summarized as follows. The authors report the successful results of a double-blind placebo-controlled study with Infliximab on several sub-types of spondyloarthropathies. For the first time, we have an effective therapeutic option for severe cases. Long-term results (more than 1 year) of patients treated in the initial open study were already disclosed in a previous publication. The future of patients suffering from spondyloarthropathy is hopeful. It seems as if all requirements have been met to allow us to hope that this treatment will be able to prevent the stiffening of the spinal column and the destruction of the peripheral joints, and that the quality of life of these patients will improve considerably.

Eric VEYS | alphagalileo

More articles from Health and Medicine:

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

nachricht The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Water - as the underlying driver of the Earth’s carbon cycle

17.01.2017 | Earth Sciences

Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

17.01.2017 | Materials Sciences

Smart homes will “LISTEN” to your voice

17.01.2017 | Architecture and Construction

VideoLinks
B2B-VideoLinks
More VideoLinks >>>